Insilico Medicine And SK Biopharmaceuticals Achieved AI-Powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
The partnership could reach $2.5 billion and combines Insilico's AI platform with SK Biopharmaceuticals' late-stage development and commercialization expertise.
- On Monday, Insilico Medicine and SK Biopharmaceuticals announced a research collaboration at the BIO 2026 International Convention to discover AI-enabled drug candidates for neuroimmune disorders.
- The partnership unites Insilico's AI-driven target-to-candidate engine with SK Biopharmaceuticals' deep CNS mastery, targeting neuroimmune disorders with historically low clinical success rates.
- Insilico will receive up to $18 million in upfront and near-term milestone payments, with total potential deal value exceeding $2.5 billion and AI-driven nomination of preclinical candidates in 12 to 18 months.
- SK Biopharmaceuticals will steer late-stage development and commercialization for all resulting programs, leveraging its U.S. commercial platform and prior success with Cenobamate for epilepsy.
- Dr. Alex Zhavoronkov, founder, co-CEO, and CBO of Insilico Medicine, said the collaboration "underscores the tremendous power of industry communication and collaboration in accelerating progress in healthcare.
29 Articles
29 Articles
Insilico and SK Biopharmaceuticals partner to develop AI-driven neuroimmune therapies
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the ce…
AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion
Insilico Medicine, the Hong Kong–listed AI drug discovery company, has signed a partnership with Korea’s SK Biopharmaceuticals to help develop new drugs for neuroimmune conditions in a deal valued at more than $2.5 billion. Insilico will use its Pharma.AI platform to help design new candidates for neuroimmune treatments, while SK Biopharmaceuticals will then steer the late-stage development and commercialization of discovered treatments. While …
keenesentinel.com
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide,…
Insilico Medicine and SK Biopharmaceuticals Forge $2.5 Billion AI-Driven
In a groundbreaking advancement for pharmaceutical innovation, Insilico Medicine and SK Biopharmaceuticals have announced an ambitious AI-powered collaboration targeting neuroimmune disorders within the central nervous system (CNS). This partnership, unveiled at the BIO 2026 International Convention, aims to accelerate the discovery and development of novel therapeutic candidates by integrating cutting-edge artificial intelligence and deep clini…
Coverage Details
Bias Distribution
- 42% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
